Phathom Pharma Upgraded by Barclays to Overweight $18 Target
Barclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Understanding the ideal retirement planning timeline is crucial for securing your future. Learn how to effectively plan your retirement.
13,883 articlesBarclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
A prominent Trump-backed bitcoin mining venture reported a heavy Q1 loss, triggering a notable slide in its shares. T...
The Department of Homeland Security is requesting $7.5 million to develop wearable facial-recognition glasses for ICE...
Standard Chartered is moving to absorb Zodia Custody's crypto operations, extending its digital-asset platform. The d...
Jaguar (JAGX) 2025 earnings show a company shifting from product-driven revenue to licensing cash. This piece breaks ...
New York moves toward banning potassium bromate in flour, potentially altering crusts and prices for thousands of piz...
Former President Donald Trump publicly supports CFTC Chair Michael Selig's push to widen federal control over predict...
As PJM prepares a March 2027 framework decision on data-center connections and pricing, investors are weighing how ne...
Brussels unveils a broad tech sovereignty package aimed at building European alternatives to U.S. cloud services and ...
The US is accelerating domestic rare-earth initiatives, and investment banks keep raising targets on MP Materials. Th...
Mind tech (mind) 2027 is shaping a new era for investors who seek durable growth in neurotech and digital mental heal...
NuScale has become a polarizing name in energy investing, swinging between hype and risk. This guide breaks down the ...